Arcus Biosciences Past Earnings Performance
Past criteria checks 0/6
Arcus Biosciences's earnings have been declining at an average annual rate of -23.2%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 27.8% per year.
Key information
-23.2%
Earnings growth rate
-11.7%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 27.8% |
Return on equity | -47.8% |
Net Margin | -102.7% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Estimating The Intrinsic Value Of Arcus Biosciences, Inc. (NYSE:RCUS)
Dec 12Arcus Biosciences, Inc.'s (NYSE:RCUS) Price Is Right But Growth Is Lacking
Nov 21Arcus Biosciences: Advancing On Several Fronts
Oct 29Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones
Sep 23Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 15Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business
Aug 19Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO
May 15Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts
May 13Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money
May 10We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth
Mar 20What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You
Feb 23Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment
Feb 22Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Dec 18Arcus Biosciences: Showing There Might Be Something To TIGIT After All
Dec 15Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?
Nov 30Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey
Nov 20Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data
Aug 29Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation
Aug 08Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates
Jun 15Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk
May 05Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17
Nov 02Revenue & Expenses Breakdown
How Arcus Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 263 | -270 | 121 | 0 |
30 Jun 24 | 247 | -249 | 121 | 57 |
31 Mar 24 | 237 | -231 | 119 | 0 |
31 Dec 23 | 117 | -307 | 117 | 0 |
30 Sep 23 | 120 | -293 | 116 | 0 |
30 Jun 23 | 121 | -287 | 112 | 147 |
31 Mar 23 | 119 | -279 | 110 | 0 |
31 Dec 22 | 112 | -267 | 104 | 0 |
30 Sep 22 | 433 | 80 | 99 | 0 |
30 Jun 22 | 409 | 67 | 89 | 0 |
31 Mar 22 | 392 | 58 | 80 | 0 |
31 Dec 21 | 383 | 53 | 72 | 0 |
30 Sep 21 | 38 | -278 | 62 | 0 |
30 Jun 21 | 93 | -199 | 57 | 0 |
31 Mar 21 | 85 | -168 | 51 | 0 |
31 Dec 20 | 78 | -123 | 43 | 0 |
30 Sep 20 | 78 | -88 | 36 | 0 |
30 Jun 20 | 15 | -112 | 33 | 0 |
31 Mar 20 | 15 | -95 | 27 | 0 |
31 Dec 19 | 15 | -85 | 25 | 0 |
30 Sep 19 | 7 | -80 | 22 | 0 |
30 Jun 19 | 9 | -69 | 18 | 0 |
31 Mar 19 | 9 | -54 | 16 | 0 |
31 Dec 18 | 8 | -50 | 14 | 0 |
30 Sep 18 | 8 | -51 | 12 | 0 |
30 Jun 18 | 4 | -63 | 11 | 0 |
31 Mar 18 | 3 | -59 | 9 | 0 |
31 Dec 17 | 1 | -53 | 8 | 0 |
Quality Earnings: RCUS is currently unprofitable.
Growing Profit Margin: RCUS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RCUS is unprofitable, and losses have increased over the past 5 years at a rate of 23.2% per year.
Accelerating Growth: Unable to compare RCUS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RCUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).
Return on Equity
High ROE: RCUS has a negative Return on Equity (-47.79%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/08 23:30 |
End of Day Share Price | 2025/01/08 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Arcus Biosciences, Inc. is covered by 15 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Peter Lawson | Barclays |
Zhiqiang Shu | Berenberg |
Jason Zemansky | BofA Global Research |